
ACADIA Pharma (ACAD) Stock Forecast & Price Target
ACADIA Pharma (ACAD) Analyst Ratings
Bulls say
ACADIA Pharmaceuticals Inc. is strategically positioned for continued growth, with expectations of approximately $1.7 billion in combined net sales by 2028, fueled by strong performance and broader community uptake of its products NUPLAZID and DAYBUE. The company has demonstrated robust sales growth, particularly with DAYBUE, achieving $110 million in the most recent quarter, which exceeded consensus estimates and reflected a significant increase in the number of patients on therapy. Additionally, ACAD's proactive expansion of its field force, now fully deployed, is projected to enhance sales further, despite recent challenges due to inflation cap rebates affecting NUPLAZID sales.
Bears say
ACADIA Pharmaceuticals faces significant risks that contribute to a negative outlook, including challenges in gaining approval for additional indications, which could adversely impact growth and market performance. Recent negative feedback regarding the trofinetide launch in the EU, along with uncertainty around the intellectual property for both NUPLAZID and DAYBUE, raises further concerns about potential market uptake and pricing stability. Additionally, high dropout rates in clinical studies for trofinetide and mixed reviews from key opinion leaders on its efficacy diminish confidence in its therapeutic value, complicating the company's prospects in addressing unmet needs in rare diseases.
This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.
ACADIA Pharma (ACAD) Analyst Forecast & Price Prediction
Start investing in ACADIA Pharma (ACAD)
Order type
Buy in
Order amount
Est. shares
0 shares